| Document |
Document Title |
|
WO/2018/225663A1 |
The purpose of the present invention is to provide a recording material and a recording sheet, in each of which a non-phenolic compound having good color-developing performance and the like is used as a color developer. A compound repres...
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/211953A1 |
The purpose of the present invention is to provide a method for safely and efficiently producing a fluorinated carbonate derivative. This fluorinated carbonate derivative production method is characterized by emitting light in the presen...
|
|
WO/2018/212511A1 |
Provided are: a self-healing polymer network containing a physical crosslinker; and a composition therefor. The self-healing polymer network comprises self-healing monomers having a first polymerizable functional group and at least one u...
|
|
WO/2018/209030A1 |
The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the ...
|
|
WO/2018/189479A1 |
The present invention relates to conjugated polymers supporting chemical probes and the use thereof for the preparation of chemical sensors based on carbon nanotubes allowing the selective detection of analytes in the water.
|
|
WO/2018/187414A1 |
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/179343A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/168573A1 |
When recovering and utilizing the urea and NH3 contained in a gas that contains urea dust and NH3 and has been discharged from a urea granulation step, an aqueous urea solution to be fed to the urea granulation step is prevented from suf...
|
|
WO/2018/170109A1 |
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins - mitoch...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/161033A1 |
Described herein are IRE1-alpha inhibitors, compositions containing such inhibitors, and methods of treatment of cancer that include administration of such compounds. Exemplary compounds are provided throughout the application.
|
|
WO/2018/154560A1 |
The invention provides aqueous hydrohalide liquid compositions containing more than 50% hydrohalide and less than 8% water. A method is provided for preparing a composition containing up to 95% urea hydrobromide, which is liquid at ambie...
|
|
WO/2018/148737A1 |
The present invention is directed to the use of a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of the symptoms of dementia with Lewy bodies, Parkinson's disease, or a combination thereof in an individual...
|
|
WO/2018/143492A1 |
The present invention relates to an aminobenzaldehyde derivative and an amino acid chiral extractant comprising the same, wherein the amino acid chiral extractant can allow amino acids in an aqueous solution to be extracted with high chi...
|
|
WO/2018/145021A1 |
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compou...
|
|
WO/2018/133756A1 |
The present invention relates to a targeted autophagy agonist and an application thereof in the treatment of neurodegenerative diseases, pertaining to the technical field of pharmaceuticals for the treatment of neurodegenerative diseases...
|
|
WO/2018/096011A1 |
The invention relates to a method for alkylating an amino compound, characterized in that at least one triazine derivative of general formula (I) or at least one urea or urea derivative of the general formula (II), (II), wherein • R4 a...
|
|
WO/2018/087019A1 |
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...
|
|
WO/2018/080007A1 |
The present invention relates to a preparation method for removing triuret causing turbidity in urea water and to urea water prepared thereby and, more specifically, to a preparation method wherein urea is introduced to de-ionized water ...
|
|
WO/2018/066646A1 |
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...
|
|
WO/2018/064559A1 |
The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose...
|
|
WO/2018/048862A1 |
The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.
|
|
WO/2018/048871A1 |
The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention furth...
|
|
WO/2018/045229A1 |
The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
|
|
WO/2018/033525A1 |
This invention relates to compounds that are agonists or partial agonists of the histamine site of the NMDA receptor, the method of preparation thereof and applications thereof.
|
|
WO/2018/018091A1 |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
|
|
WO/2018/019987A1 |
The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylat...
|
|
WO/2018/007986A1 |
I n the process of the present invention, cariprazine is prepared by converting (trans-4-amino- cyclohexyl)-acetic acid ethyl ester hydrochloride to trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis, from the obtain...
|
|
WO/2018/005625A1 |
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...
|
|
WO/2017/188551A1 |
The present invention relates to a novel N-acylurea derivative and use thereof in the treatment or prevention of cardiovascular diseases and, more particularly, to a novel N-acylurea derivative, a pharmaceutical composition comprising th...
|
|
WO/2017/183723A1 |
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...
|
|
WO/2017/180323A1 |
The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide re...
|
|
WO/2017/172761A1 |
The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPRl a...
|
|
WO/2017/168024A1 |
The invention relates to polyphenol compounds derived from amide and urea and to the use thereof as antioxidants, as well as to pharmaceutical, cosmetic and food compositions, inter alia, comprising same.
|
|
WO/2017/156164A1 |
The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present inve...
|
|
WO/2017/154019A1 |
The present invention relates to an improved process for the preparation of 1,3-bis(2-chloroethyl)-1 -nitrosourea compound of formual-1 which is represented by the following structural formula:
|
|
WO/2017/139414A1 |
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases)...
|
|
WO/2017/132023A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing suc...
|
|
WO/2017/099232A1 |
[Problem] To provide a novel gelling agent containing a mono-urea derivative. [Solution] A gelling agent comprising a compound represented by formula [1] (in the formula, R1 represents a C2-20 straight chain or branched chain alkyl group...
|
|
WO/2017/095969A1 |
The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the char...
|
|
WO/2017/070482A2 |
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
|
|
WO/2017/063091A1 |
The present disclosure relates to a compound that has biocidal activity or is a precursor of a compound with biocidal activity. The compound comprises an N-halamine precursor, at least one quaternary ammonium and at least one coating-inc...
|
|
WO/2017/062856A1 |
A synergistic agricultural formula including at least one diacyl or diaryl urea, such as a Ν,Ν'-diformylurea, and at least metal complex, such as metal complexes of cobalt, nickel, silver or other metals, is applied to plants at physio...
|
|
WO/2017/055552A1 |
The invention relates to the field of polyisocyanate compositions for the production of coatings and adhesives. The composition according to the invention combines a polyisocyanate compound with biuret motifs, a protic, polar reactive di...
|
|
WO/2017/056832A1 |
Provided is an active-light-sensitive or radiation-sensitive composition that contains (A) a compound having two or more of the structures represented by general formula (1), the compound not having an acid crosslinking group, and (B) a ...
|
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
|
WO/2017/044314A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
